Carmafil Launches Newly Designed Guidewire Bowl – Now Commercially Available

April 8, 2021

Carmafil, LLC is excited to announce the launch of a newly designed guidewire bowl that helps specialists be more efficient during endovascular procedures.

Developed by vascular/endovascular neurosurgeon Dr. Cargill Alleyne, this uniquely designed product is now available for commercial use.

A variety of doctors (neurosurgeons, neurologists, radiologists, cardiologists, vascular surgeons, and cardiac surgeons) use catheters and wires to fix blood vessel problems in the body through a minimally invasive approach.  These filaments are housed in a bowl filled with saline to keep them hydrated.  The patent-pending Carmafil guidewire bowl solves the problem of having a tangle of wires and catheters at the bottom.  The new bowl has a staircase design along the inside wall which segregates the wires to make it easier to retrieve them.  Other key features are:

–          It holds up to 4 wires or catheters

–          The wires or catheters can easily be retrieved with one hand

–          It reduces potential contamination during retrieval

–          The light blue color facilitates visualization of the wires in dim lighting

–          It was designed by a practicing neuro interventionalist and an engineer.

“As a busy clinician, I’m constantly seeking ways to increase efficiency in the operating room and the angiography suite.  This modification to the standard guidewire bowl goes a long way toward that end” says co-inventor and company CEO Dr. Cargill Alleyne.  He is a dually trained, vascular/endovascular neurosurgeon in private practice at University Hospital Augusta Back in Augusta, GA. Dr. Alleyne is the former Chairman and Residency Program Director of the Department of Neurosurgery, Medical College of Georgia, Augusta University.  The other co-founder Mahmoud Baniasadi, Ph.D. is an Assistant Professor in the Allen E. Paulson College of Engineering and Computing, Department of Manufacturing Engineering at Georgia Southern University.

Carmafil, LLC manufactures a unique guidewire bowl which was developed from the collaboration of a dually trained open/endovascular neurosurgeon and an engineer.

The company has been nationally certified as a Minority Business Enterprise by the Georgia Minority Supplier Development Council.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”